Key result
Pharmacological therapies for cardiovascular injury focus on modifying the inflammatory response in both chronic atheromatous lesions and intimal hyperplasia associated with acute vascular intervention.
This review summarizes current and future pharmacological therapies targeting the inflammatory response in vascular injury, including chronic atherosclerosis and acute intimal hyperplasia.
Review frames atherosclerotic therapies by inflammatory response to injury; extends mechanistic model but leaves open targeted trials.
Vascular injury is a ubiquitous phenomenon which can be both occult (such as with hyperlipidemia) and overt (such as with angioplasty). While the exact pathophysiology differs between acute and chronic atherosclerosis, both lesions can be mechanistically explained by the vasculature's exaggerated response to injury. Pharmacological attempts to treat atherosclerotic cardiovascular disease can be categorised by their role in modifying this inflammatory response. This manuscript reviews current therapy for cardiovascular injury at two levels: the chronic smouldering atheromatous lesion and intimal hyperplasia associated with acute vascular intervention. In addition, future therapeutic strategies, based within this inflammatory paradigm, are discussed.
No takes yet. Share an insight, caveat, or question.
Craig H. Selzman (2001) conducted a review in Vascular injury and atherosclerotic cardiovascular disease. Pharmacological therapy for vascular injury was evaluated. Pharmacological therapies for cardiovascular injury focus on modifying the inflammatory response in both chronic atheromatous lesions and intimal hyperplasia associated with acute vascular intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: